Press Releases Incyte Corporation

Equities

INCY

US45337C1027

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 01:30:00 22/04/2026 am IST			5-day change	1st Jan Change
96.22 ^USD	-0.72%		-1.50%	-2.58%

22/04	Incyte Insider Sold Shares Worth $1,801,366, According to a Recent SEC Filing	MT
21/04	Incyte Highlights New Phase 3 Tafasitamab Data At the 2026 American Society of Clinical Oncology Annual Meeting	CI

Press Releases

21/04	Incyte Highlights New Phase 3 Tafasitamab Data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting	BU
09/04	Incyte to Report First Quarter Financial Results	BU
29/03	Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting	BU
25/03	Incyte Announces Executive Leadership Appointments	BU
20/03	Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting	BU
07/03	Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)	BU
02/03	Lilly's Olumiant recommended by CHMP for approval of expanded use in the European Union for adolescents with severe alopecia areata	AQ
27/02	Lilly's Olumiant (baricitinib) recommended by CHMP for approval of expanded use in the European Union for adolescents with severe alopecia areata	PR
17/02	Incyte to Present at Upcoming Investor Conferences	BU
10/02	Incyte : Q4 Financial Results (9f9c55db 154c 4d4a b532 7ff5493de577)	PU
10/02	Incyte: Q4 Earnings Snapshot	AQ
10/02	Incyte Reports Fourth Quarter and Full Year 2025 Financial Results	BU
30/01	Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)	BU
30/01	Thin Disclosure But "Bulletproof" Protection: How A Salt Form Patent Was Upheld In China Despite Minimal Data	AQ
27/01	Incyte to Report Fourth Quarter and Year-End 2025 Financial Results	BU
12/01	Incyte : JP Morgan Healthcare Conference Presentation	PU
05/01	Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for Diffuse Large B-Cell Lymphoma	BU
22/12	Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma	BU
22/12	Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer	BU
18/12	Incyte to Present at Upcoming Investor Conference	BU
18/12	Incyte Announces European Commission Approval of Minjuvi(R) (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma	AQ
17/12	Incyte Announces European Commission Approval of Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma	BU
12/12	Incyte Announces Change to its Board of Directors	BU
09/12	Incyte Presents Updated Positive Data at ASH 2025 Reinforcing the Potential of INCA033989, its First-in-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Essential Thrombocythemia	BU
07/12	Incyte : First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDA	PU